Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice
Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice
复制标题
DOI：
10.1016/j.micinf.2014.02.011
复制
发表时间：
2014-06-01
影响因子：
5.8
通讯作者：
Matsuzaki, Shigenobu
中科院分区：
文献类型：
--
作者：
Takemura-Uchiyama, Iyo;Uchiyama, Jumpei;Matsuzaki, Shigenobu
耐甲氧西林金黄色葡萄球菌(MRSA)引起的院内呼吸道感染可发展为致命性全身感染。噬菌体(噬菌体)疗法有望对这些严重感染有效。此前，噬菌体S13‘被认为是一种潜在的治疗噬菌体。在这里，我们使用噬菌体S13‘对肺源性败血症的小鼠模型进行了噬菌体治疗。感染后6h腹腔注射噬菌体，可减轻感染严重程度，挽救感染小鼠。噬菌体S13‘在体外能有效地裂解引起肺炎相关细菌的医院获得性MRSA菌株。因此，噬菌体疗法可能是葡萄球菌肺源性败血症的一种可能的治疗干预措施。(C)2014年巴斯德研究所。爱思唯尔·马森公司出版。版权所有。
Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) can progress to lethal systemic infections. Bacteriophage (phage) therapy is expected to be effective against these critical infections. Previously, phage S13' was proposed as a potential therapeutic phage. We here examined phage treatment in a mouse model of lung-derived septicemia using phage S13'. Intraperitoneal phage administration at 6 h postinfection reduced the severity of infection and rescued the infected mice. Phage S13' can efficiently lyse hospital-acquired MRSA strains causing pneumonia-associated bacterernia in vitro. Thus, phage therapy may be a possible therapeutic intervention in staphylococcal lung-derived septicemia. (C) 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.